Patents
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
04/2003
04/24/2003WO2002056900A3 Use of slpi for treating chronic inflammatory intestinal diseases
04/24/2003WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003US20030078438 N-heterocyclicamide compounds; used as anticoagulant agent
04/24/2003US20030078427 Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
04/24/2003US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases
04/24/2003US20030078405 47 human secreted proteins
04/24/2003US20030078304 Administering to animal or man of at least one type of xanthophyll in an amount inhibiting the expression of inflammatory cytokines and chemokines in animal or man
04/24/2003US20030078300 Fused bicyclic or tricyclic amino acids
04/24/2003US20030078299 Anti-cancer nitro- and thia-fatty acids
04/24/2003US20030078279 For therapy and prophylaxis of pain, central nervous system disorder or the like in mammalian subjects
04/24/2003US20030078278 Spiropiperidine compounds as ligands for ORL-1 receptor
04/24/2003US20030078277 For therapy and prophylaxis of depression; Tourette syndrome, autism, bipolar disorder, cyclothymia, schizophrenia, Alzheimer disease, obesity, diabetes, alcohol dependence, sleep disorder, insomnia, migraine, stress headache, etc.
04/24/2003US20030078276 Matrix metalloproteinase inhibitors
04/24/2003US20030078275 For therapy of cancer, diabetes and Alzheimer's disease
04/24/2003US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
04/24/2003US20030078265 Inhibitors of nitric oxide synthase (nos)
04/24/2003US20030078260 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
04/24/2003US20030078259 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders
04/24/2003US20030078258 Adrenergic blocking agents
04/24/2003US20030078246 Combinations for the treatment of inflammatory disorders
04/24/2003US20030078239 Ketone compounds and compositions for cholesterol management and related uses
04/24/2003US20030078236 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003US20030078214 Phytooestrogen selected from genistein, daidzein; for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia
04/24/2003US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
04/24/2003US20030078166 Pyrazole compounds useful as protein kinase inhibitors
04/24/2003US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
04/24/2003US20030077802 Human PRL1 phosphatase
04/24/2003US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof
04/24/2003US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor
04/24/2003US20030077585 Nucleotide sequences coding polypeptide for use in the diagnosis, detection, prevention and treatment of bacterial infection
04/24/2003US20030077568 Screening drugs; obtain cell with preferential phenotypic profile, incubate with drug, monitor effect on cells
04/24/2003US20030077565 Preservation of corneal graft in vitro; obtain graft, incubate with antisense oligonucleotides in solution, monitor viability of graft tissue
04/24/2003US20030077327 Highly compressible ethylcellulose for tableting
04/24/2003US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
04/24/2003US20030077271 Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders
04/24/2003US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer
04/24/2003US20030077246 TNFr/OPG-like molecules and uses thereof
04/24/2003CA2727642A1 Synthesis of cyclosporin analogs
04/24/2003CA2463850A1 Remodeling of tissues and organs
04/24/2003CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003CA2463724A1 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
04/24/2003CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
04/24/2003CA2463682A1 Method of reducing type 2 diabetes in high risk patients
04/24/2003CA2463159A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
04/24/2003CA2462980A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
04/24/2003CA2462442A1 Alkyne matrix metalloproteinase inhibitors
04/24/2003CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
04/24/2003CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003CA2461245A1 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
04/24/2003CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003CA2459572A1 Composition comprising a lactobacillus pentosus strain and uses thereof
04/23/2003EP1304324A1 Serotonin reuptake inhibitors
04/23/2003EP1304322A2 Carboxylic acid compound and use thereof
04/23/2003EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
04/23/2003EP1303632A2 Galactomannan oligosaccharides and methods for the production and use thereof
04/23/2003EP1303625A2 Alpha-msh related compounds and methods of use
04/23/2003EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction
04/23/2003EP1303541A1 Gel compositions containing metronidazole
04/23/2003EP1303527A1 Matrix metalloproteinase inhibitors
04/23/2003EP1303521A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives
04/23/2003EP1303520A1 Therapeutic compounds and methods
04/23/2003EP1303519A1 Tricyclic imidazopyridines
04/23/2003EP1303517A1 Indoloquinazolinones
04/23/2003EP1303513A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
04/23/2003EP1303507A1 Pyrimidine derivatives
04/23/2003EP1303506A1 6-heteroarylphenanthridines
04/23/2003EP1303503A2 Aniline derivatives
04/23/2003EP1303501A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
04/23/2003EP1303499A1 Tetrazole derivatives
04/23/2003EP1303492A2 Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
04/23/2003EP1303490A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
04/23/2003EP1303487A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
04/23/2003EP1303486A1 Pyrrolidine derivatives as metalloprotease inhibitors
04/23/2003EP1303485A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
04/23/2003EP1303477A2 1-amino-alkylcyclohexanes as 5-ht3- and neuronal nicotinicreceptor antagonists
04/23/2003EP1303312A2 Diagnosis of liver disease
04/23/2003EP1303304A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
04/23/2003EP1303302A2 Use of strains of the parapox ovis virus against organ fibrosis
04/23/2003EP1303286A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
04/23/2003EP1303266A1 Treatment of eating disorders using carboxyalkylethers
04/23/2003EP1303192A1 Dietary lipids for improving skin and coat of pets
04/23/2003EP1250055A4 Immune modulation with death receptor-induced apoptosis
04/23/2003EP1220863B1 Purine derivatives
04/23/2003EP1100488B1 Use of creatine compounds for treatment of bone or cartilage cells and tissues
04/23/2003EP1094807B1 Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies
04/23/2003EP1058535B1 Desensitizing dental composition
04/23/2003EP1045690B1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
04/23/2003EP1035848B1 Substituted alkanohydroxamic acids and method of reducing tnf-alpha levels
04/23/2003EP1020474B1 Oligosaccharide derivatives and process for producing the same
04/23/2003EP0937041B1 Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
04/23/2003EP0795025B1 Enantioselective preparation of pharmaceutically active sulfoxides by bioreduction
04/23/2003CN1413250A Method of producing differentiated progenitor cells and lineage-defective embryonic stem cells
04/23/2003CN1413213A Azaindoles
04/23/2003CN1413211A Substituted 1,3,4-oxadiazoles and method of producing TNF-alpha levels
04/23/2003CN1413210A Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases